Premium
Pharmacokinetic alternation of mitiglinide in depression model rats (657.3)
Author(s) -
Xu Feng
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.657.3
Subject(s) - depression (economics) , cmax , open field , pharmacokinetics , medicine , endocrinology , animal model , pharmacology , diabetes mellitus , economics , macroeconomics
Many diabetes patients suffer from wild to severe depression. It is unclear that depression might alter the drug metabolic process of the hypoglycemic agents or not. We conducted an animal experiment to study the impact. Eighteen Sprague‐Dawley rats were randomized into depression model group and control group. The 9 depression rats were established by exposing to chronic unpredicted mild stresses (CUMS) for 8 weeks. Open‐field test and 5‐HT levels were assayed to evaluate the depression. All rats were given 2.5mg/kg of mitiglinide (MGN) per os. MGN plasma concentration was measured by HPLC‐MS/MS. Statistical moment analysis was processed with DAS software. Open‐field test and 5‐HT levels measurement results confirmed the depression model. Cmax, Tmax, AUC0→∞, MRT0→∞, and T1/2z were reduced while CLz/F was increased in depression model rats compared to control rats. These preliminary results suggest that depression might alter the drug metabolic process of MGN. Grant Funding Source : Supported by Shanghai Fengxian Science and Technology Research Project